/ EN
2026-06-30 00:00 United States Policy & Regulation Regulatory Approval Translated from EN

FDA Clears Ceribell Monitor for Bedside EEG Recording

Summary The FDA cleared the Ceribell Monitor on June 30, 2026, finding it substantially equivalent under submission number K261101 through the traditional 510(k) pathway. The agency classifies it as a Reduced-Montage Standard Electroencephalograph, a Class II device under regulation 882.1400, with neurology as the assigned review panel. It is one of several Ceribell clearances in the same period; the product line is built around rapid reduced-montage setup for bedside recording in emergency and critical care.
Why it matters Several clearances in the same window read as a company scaling a product line rather than testing a concept, the phase in which bedside EEG competes on setup time and staffing rather than on signal quality.

BCIwiki (bciwiki.com) — Ceribell, Inc. received an FDA 510(k) decision of Substantially Equivalent for Ceribell Monitor on June 30, 2026, under submission number K261101. The submission followed the Traditional 510(k) clearance pathway.

FDA lists the product under the device classification name Reduced- Montage Standard Electroencephalograph. It is a Class 2 device under regulation number 882.1400, assigned to the Neurology advisory committee. This is one of several Ceribell clearances in the same period; the product line is built around rapid reduced-montage setup for bedside recording in emergency and critical care.

Compiled by BCIwiki from public sources

Sources · 1

Ceribell timeline

2026-06 FDA Clears Ceribell Neurology Review Software 2025-12 FDA Clears Ceribell Delirium Monitor System 2025-11 FDA Clears Ceribell Infant Seizure Software All entries →
Read original ↗
Suggest a correction Revisions · none / EN
© 2026 BCIwiki.com Digest Topics Tips Subscribe Revisions About